Cyclic Nucleotides as Targets for Drug Design
- 1 January 1977
- book chapter
- Published by Elsevier
- Vol. 12, 1-38
- https://doi.org/10.1016/b978-0-12-013312-3.50004-2
Abstract
No abstract availableThis publication has 100 references indexed in Scilit:
- Increase in type I adenosine 3′,5′-monophosphate-dependent protein kinase during isoproterenol-induced cardiac hypertrophyBiochemical and Biophysical Research Communications, 1976
- Stimulation of membranous guanylate cyclase by concentrations of calcium that are in the physiological rangeBiochemical and Biophysical Research Communications, 1976
- Specificity of the dopamine sensitive adenylate cyclase for antipsychotic antagonistsLife Sciences, 1976
- Effect of N6, 2′-O-dibutyryl cyclic AMP upon the interconvertible forms of cyclic AMP phosphodiesterase from human plateletsBiochemical and Biophysical Research Communications, 1975
- Lipolysis and adenosine 3?5?-cyclic monophosphate in adipose tissue of the New Zealand obese mouse; the activities of adipose tissue adenyl cyclase and phosphodiesteraseDiabetologia, 1974
- Epinephrine binding by rat liver plasma membranes: Effect of guanyl nucleotidesBiochemical and Biophysical Research Communications, 1974
- The influence of p, p'-DDT, α-chlordane, heptachlor and endrin on hepatic and renal carbohydrate metabolism and cyclic AMP-adenyl cyclase systemLife Sciences, 1973
- Possibilities for drug development based on the cyclic AMP systemLife Sciences, 1973
- Cyclic 3′,5′-nucleotide phosphodiesterase, IV. Two enzymes with different properties from brainBiochemical and Biophysical Research Communications, 1971
- Cyclic 3′,5′-nucleotide phosphodiesteraseBiochemical and Biophysical Research Communications, 1970